Independent Grants for Learning & Change (IGLC)
October 1, 2014
Webinar Agenda

- Introduction – Bob Kristofco
- Review of RFP and CGA process – Amanda Stein
- Clinical areas of interest planned for 2015 – Amanda Stein
- Open grant opportunities & FAQs – Jackie Waldrop & Susan Connelly
- Sunshine Act reporting – Ericka Eda
- Q & A – Maureen Doyle-Scharff and full team
Pfizer’s Independent Grants Program

Learning & Change (Track 1)
- RFPs
  - Increase the competence and performance of individual providers and healthcare teams
  - Educate and empower patients
  - Remove barriers and implement solutions within systems-of-care
  - MOC Part 4 initiatives
  - RFP-driven with ERP decision making
  - Meaningful partnerships

Knowledge Gaps (Track 2)
- Annual Meetings
  - Emerging Science/Knowledge Exchange; Traditional CME/CE
  - Major congresses, conferences, community programs of key stakeholder organizations
- Call for Grant Applications (CGAs)
  - Live, virtual, enduring and ongoing programs (e.g., web, print, series)
  - Board review courses, grand rounds series, MOC Part 2 initiatives

Healthcare Charitables
- Patient education, including health screening
- Patient advocacy for disease awareness
- Patient access to care (e.g., transportation costs)
What is the difference between an RFP and a CGA?

**Request for Proposals**
- Considered “Track 1 Learning & Change”
- External Review Panel (or Partner Org) makes decisions
- Budget typically more than $1M
- 6 month process
- Two step application process (LOI and Full Proposal)
- RFP is extensive summary of gap in patient care to be targeted
- Feedback from External Review Panel provided at LOI stage and upon final decision

**Call for Grant Applications**
- Considered “Track 2 Knowledge Exchange”
- Internal review & decision making
- Budget typically less than $1M
- 3 month process
- One step application process (details included in posting)
- CGA is brief statement of clinical area goal
- Limited information on grant decision rationale available from grant officer upon request.
Where are they posted?

Request for Proposals

www.pfizer.com/independentgrants
in the Request for Proposals section

Call for Grant Applications

www.pfizer.com/independentgrants
in the Grants Process section

Request for Proposals

Pfizer will publish evidence-based, data driven Request for Proposals (RFPs) in key clinical areas where gaps have been identified through external entries, registries and other assessment methodologies and processes. Each RFP will focus on areas where Pfizer support could potentially have the greatest impact on improved patient care and outcomes.

<table>
<thead>
<tr>
<th>RFP ID#</th>
<th>RFP Issue Date</th>
<th>Request for Proposal</th>
<th>Common Questions &amp; Answers</th>
<th>External Review Panel (ERP) Members</th>
<th>LOI Due Date</th>
</tr>
</thead>
<tbody>
<tr>
<td>2014SC2</td>
<td>September 3, 2014</td>
<td>Smoking Cessation</td>
<td>Send questions to <a href="mailto:Jacqueline.Waldrop@pfizer.com">Jacqueline.Waldrop@pfizer.com</a></td>
<td>TBA</td>
<td>October 23, 2014</td>
</tr>
</tbody>
</table>

*All posting are also distributed via email to all registered users of our Grant Management System*
Frequently Asked Questions?

Q: When are RFPs and CGAs posted?
A: IGLC expects to release 1-3 RFPs per clinical area per year.

CGAs are posted throughout the year based on educational strategies specially designed to close gaps in knowledge and improve competence in certain clinical areas.

Each RFP and CGA will contain its own deadlines.

Q: Can overhead/indirect costs be included?
A: Institutional overhead and indirect costs can be included within the grant request. Pfizer maintains a company-wide, maximum allowed overhead rate of 28% for independent initiatives.
# Planned Clinical Areas of Interest – remainder of 2014 and 2015

<table>
<thead>
<tr>
<th>Topic</th>
<th>RFP or CGA</th>
<th>Approx. timeframe (if known)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Pain</td>
<td>RFP</td>
<td>Q4 2014</td>
</tr>
<tr>
<td></td>
<td>RFP</td>
<td>Q1/Q2 2015</td>
</tr>
<tr>
<td></td>
<td>CGA*</td>
<td>Q2 2015</td>
</tr>
<tr>
<td>Women’s Health</td>
<td>RFP</td>
<td>Q2 2015</td>
</tr>
<tr>
<td>Rheumatoid Arthritis</td>
<td>RFP</td>
<td>Q4 2014</td>
</tr>
<tr>
<td></td>
<td>RFP</td>
<td>Q2 2015</td>
</tr>
<tr>
<td></td>
<td>CGA</td>
<td>Q4 2014</td>
</tr>
<tr>
<td></td>
<td>CGA</td>
<td>Q3 2015</td>
</tr>
<tr>
<td>Dermatology- Psoriasis</td>
<td>RFP</td>
<td>Q1/Q2 2015</td>
</tr>
<tr>
<td></td>
<td>CGA*</td>
<td>Q3 2015</td>
</tr>
</tbody>
</table>

*Tentative
<table>
<thead>
<tr>
<th>Topic</th>
<th>RFP or CGA</th>
<th>Current approx. timeframe (if known)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Cardiovascular – lipids</td>
<td>RFP</td>
<td>Q3 2015</td>
</tr>
<tr>
<td>Cardiovascular – anticoagulation*</td>
<td>RFP</td>
<td>Q4 2014</td>
</tr>
<tr>
<td>Vaccines</td>
<td>RFP</td>
<td>Q4 2014</td>
</tr>
<tr>
<td></td>
<td>RFP</td>
<td>Q1 2015</td>
</tr>
<tr>
<td></td>
<td>RFP</td>
<td>Q2 2015</td>
</tr>
<tr>
<td>Oncology – Breast</td>
<td>RFP</td>
<td>Q2 2015</td>
</tr>
<tr>
<td>Oncology - Breast</td>
<td>possible CGA under discussion</td>
<td>Q4 2014</td>
</tr>
<tr>
<td>Oncology - RCC</td>
<td>CGA</td>
<td>Q4 2014</td>
</tr>
<tr>
<td>Oncology - CML</td>
<td>CGA</td>
<td>Q4 2014</td>
</tr>
<tr>
<td>Oncology - Lung</td>
<td>TBD</td>
<td>TBD</td>
</tr>
</tbody>
</table>

*With BMS
Other 2015 Clinical Areas of Interest

For 2015 IGLC expects to support similar areas of interest as in the current year. Please visit our websites in November/December for the latest updates.

• **Track 2 – Knowledge Gap (Annual Meetings)**
  [www.pfizer.com/independentgrants](http://www.pfizer.com/independentgrants) in the *Grants Process* section

• **Healthcare Charitable Contributions**
  [www.pfizer.com/healthcarecharitables](http://www.pfizer.com/healthcarecharitables) in the *Latest Update* section
Current RFP/CGA Open for Submissions

• Smoking Cessation RFP (U.S. only)
• Deadline for LOI submissions: October 23rd 2014
• Answers from some FAQs. (Full list available in the webinar resources area)
Current RFP/CGA Open for Submissions

CGA: Knowledge Gaps in Inflammatory Bowel Disease

• Deadline for LOI submissions: Oct 16, 2014

• Answers from some FAQs
  – Alternate budget templates can be used
  – Indirect costs are capped at 28%
  – Grant funds cannot be used for food and beverage for participants
Sunshine Act reporting

Track 1 – Learning & Change (RFP / two-stage application process)

• Funding from IGLC is NOT considered by Pfizer as a research grant under the Sunshine Act.

• Sunshine Act reporting is collected as follows:
  ➢ During the lifespan of the project at semi-annual intervals
    o Jan-Jun reporting period collected in July
    o Jul-Dec reporting period collected in January
  ➢ Upon completion of the project as part of the reconciliation/closeout process
Sunshine Act reporting (cont’d)

Track 2 – Knowledge Gap (Annual Meetings & CGAs)

• Funding from IGLC may **NOT** be used to purchase/distribute “items of value” which are items that possess a discernible value on the open market such as textbooks for faculty or learners/participants.

• Sunshine Act reporting is collected at the conclusion of the supported activity or earlier upon Pfizer’s request in order to meet specific Sunshine Act reporting commitments.

Healthcare Charitable Contributions

• Sunshine Act reporting is collected at the conclusion of the supported program or earlier upon Pfizer’s request in order to meet specific Sunshine Act reporting commitments.
Reminders & Requirements

• Funds from Pfizer IGLC may **NOT** be used for food & beverages (F&B) for learner/participants in any way or for any reason—this applies across all grant types.

  ➚ Budgets submitted may include F&B but by signing a letter of agreement, your organization agrees that Pfizer IGLC funds will not be used for F&B for learners/participants.

• Track 1 and Track 2 are education grants, not research grants.

• Pfizer must collect and consolidate a high volume of data across its various divisions, business units, and departments who are all interacting with numerous external organizations. Collecting data before the CMS deadline or periodically aids us with that process.
Reminders & Requirements (cont’d)

• Regardless of whether your organization is a teaching hospital, if your organization made non-excluded payments or transfers-of-value to covered recipients using funds received from Pfizer, you must provide the required information to Pfizer within the specified timeframe. This data will be collected according to the terms and conditions included in the letter of agreement signed at the time Pfizer approved your grant.

• If the payments your organization made to a teaching hospital were ultimately provided to physicians, report those payments for each physician—do not report the payments made to the teaching hospital when the teaching hospital is only serving as intermediary.
Reminders & Requirements (cont’d)

• Failure to submit the required information to Pfizer within the specified timeframe is viewed as non-compliance with the terms and conditions in the letter of agreement, i.e., breach of contract with Pfizer. In addition to other legal remedies, failure to provide Pfizer with the required information in a timely manner may result in Pfizer canceling the grant or seeking recovery of the funds. Pfizer may also deny future grants to your organization.

• All reportable data must be entered in the *Sunshine Data Template*. Organizations may not use their own format—Pfizer must submit reportable data to CMS in a uniform, consistent format.
Tips for **Sunshine Data Template**

- The *Sunshine Data Template* is accessible in the Grant Management System. Organizations will be prompted to take action when due.

- Remember to enable macros prior to filling out the template.

- Upon completion, save the template as an Excel file on your computer, then upload the completed file to the Grant Management System.

- When submitting reportable data, only upload **completed** Sunshine templates. If not applicable, e.g., your organization did not make any payments to covered recipients using Pfizer IGLC funds, please do not upload empty files.
Tips for *Sunshine Data Template* (cont’d)

**Total Amount Received from Pfizer**

Total grant amount your organization received from Pfizer IGLC for the specific project/activity.

**Amount from Pfizer Allocated to Physicians and Teaching Hospitals**

Sum of payments and transfers of value which your organization provided to covered recipients using funds from Pfizer IGLC. ***For Track 1-RFP grants (projects spanning multiple years), include only those payments made during the respective reporting period (e.g., July-Dec 2014).***
Tips for *Sunshine Data Template* (cont’d)

**Date of Interaction**

Enter the date of the supported activity. ***For Track 1-RFP grants, enter the date your organization made the payment or transfer of value to the covered recipient. If multiple payments were made over the course of the respective reporting period, enter the most recent date a payment was made or the last date of the reporting period.***

**NOTE:** Among other things, you must identify each covered recipient’s name, business address, and NPI; the amount and date of each payment or transfer-of-value; and the payment’s category.
Resources

• Latest Sunshine reporting FAQs to be posted on IGLC website after today’s webinar.

• For questions about reporting requirements with regard to the Pfizer independent grants program, contact IGLC@pfizer.com.

• To learn more about the Sunshine Act, visit the Official Website for Open Payments (Sunshine Act) http://www.cms.gov/Regulations-and-Guidance/Legislation/National-Physician-Payment-Transparency-Program/index.html